Tumor metastasis blockade
Inhibits tumor cell migration, reducing the spread of bone metastases.
Our Science
ICOS-Fc: innovation & technology
A new immunologic approach to treat cancer and bone-loss related diseases.
The molecule
NOVAiCOS ImmunoTherapeutics develops cutting-edge biotechnological solutions based on immunotherapy for the treatment of primary tumors, bone metastases and bone loss-related diseases.
At the core of our technology is ICOS-Fc, a new generation biological drug that enhances the effector and regulatory functions of various types of T cells and targets the ICOS/ICOSL immune pathway to block tumor progression, reduce osteolysis, and improve patients’ quality of life.
NOVAiCOS innovation lies in its ability to simultaneously address multiple aspects of the disease
Tumor growth inhibition
Prevents the formation of tumor angiogenesis, blocking the growth of cancer cells.
Restoration of immune balance
Enhances the immune response against tumors, increasing the effectiveness of T cells in recognizing and destroying cancer cells.
Bone protection
Blocks bone resorption by inhibiting osteoclasts, reducing the risk of fractures.
Cells targeted by ICOS-Fc
-
Osteoclasts -
Tumor cells -
Cancer vascular cells -
Immune cells
Through the application of advanced nanotechnology, NOVAiCOS aims to enhance the effectiveness of ICOS-Fc in treating primary tumors and bone metastases, with the goal of inhibiting metastatic tumor growth and reducing fracture incidence, ultimately improving patient survival and quality of life.
A unique approach
Immunotherapy and nanotechnology
By combining molecular biology and advanced nanotechnologies, we can identify three key innovations.
- 01
The use of ICOS-Fc as a single drug for osteolysis, tumor growth and metastases represents a significant innovation, combining both antitumor and antiosteolytic effects in a single therapy.
- 02
Identifying an optimal delivery system for ICOS-Fc targeted to the tumor microenvironment is essential. The use of nanoparticles for selective drug transport represents a significant innovation.
- 03
Unlike conventional immunotherapeutics that primarily target lymphocytes, ICOS-Fc offers a multifunctional approach: it reduces immunosuppression, enhances T cell activity, modulates the tumor microenvironment, and directly inhibits tumor cell proliferation and metastasis.
NOVAiCOS’ approach represents a breakthrough in bone metastasis therapy, offering a targeted and innovative treatment.